期刊
CANCER CELL
卷 3, 期 1, 页码 63-74出版社
CELL PRESS
DOI: 10.1016/S1535-6108(02)00238-6
关键词
-
资金
- NCI NIH HHS [R21-CA89888, P30-CA68485, R01-CA89674, P50-CA90949, R01-CA70937, R01-CA88076, R01-CA58508] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA070937, R21CA089888, P30CA068485, R01CA058508, P50CA090949, R01CA089674, R01CA088076] Funding Source: NIH RePORTER
The objective of this study was to target drug delivery to radiation-induced neoantigens, which include activated receptors within the tumor vasculature. These responses include posttranslational changes in pre-existing proteins, which can be discovered by phage-displayed peptide libraries administered to mice bearing irradiated tumors. Phage-displayed peptides recovered from irradiated tumors included the amino acid sequence RGDGSSV. This peptide binds to integrins within the tumor microvasculature. Immunohistochemical staining of irradiated tumors showed accumulation of fibrinogen receptor alpha(2b)beta(3) integrin. We studied tumor targeting efficiency of ligands to radiation-induced alpha(2b)beta(3). Radiopharmaceuticals were localized to irradiated tumors by use of alpha(2b)beta(3) ligands conjugated to nanoparticles and liposomes. Fibrinogen-conjugated nanoparticles bind to the radiation-activated receptor, obliterate tumor blood flow, and significantly increase regression and growth delay in irradiated tumors. Radiation-guided drug delivery to tumor blood vessels is a novel paradigm for targeted drug delivery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据